Progress of invasive pulmonary aspergillosis in patients with hematological diseases

doi:10.3877/cma.j.issn.1674-1358.2022.03.001

Abstract

Abstract:

Invasive pulmonary aspergillosis (IPA) is the main cause of death of fungal infection in patients with hematologic malignancies, especially in those receiving allogeneic hematopoietic stem cell transplantation. Early diagnosis and treatment is crucial to reduce morbidity and improve the prognosis. However, although the diagnosis and treatment of IPA had laboratory biology indexes, pathological and radiological data to support, and has formed a relatively complete system of diagnosis and treatment, but restricted to difficult obtain of the specimen, non-specific clinical features and prevented use of antifungal drugs, early diagnosis is still challenged. This article will discuss the understanding of IPA and related research progress on the pathogenesis, clinical manifestations, diagnostic criteria, current technologies including imaging and laboratory testing, and next-generation gene sequencing (NGS) applications in patients with hematological malignancies.

Key words: Hematological malignancies, Invasive pulmonary aspergillosis, Next generation sequencing

Dan Feng, Erlie Jiang. Progress of invasive pulmonary aspergillosis in patients with hematological diseases[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2022, 16(03): 145-149.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2022.03.001

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2022/V16/I03/145

References 31

[1]	Azoulay E, Russell L, Van de Louw A, et al. Diagnosis of severe respiratory infections in immunocompromised patients[J]. Intensive Care Med,2020,46(2):298-314.
[2]	Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database[J]. Clin Infect Dis,2010,50(8):1091-100.
[3]	Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance[J]. J Infect Dis,2004,190(3):641-649.
[4]	Chiu CY, Miller SA. Clinical metagenomics[J]. Nat Rev Genet,2019,20(6):341-355.
[5]	van de Veerdonk FL, Gresnigt MS, Romani L, et al. Aspergillus fumigatus morphology and dynamic host interactions[J]. Nat Rev Microbiol,2017,15(11):661-674.
[6]	Gravelat FN, Beauvais A, Liu H, et al. Aspergillus galactosam-inogalactan mediates adherence to host constituents and conceals hyphal beta-glucan from the immune system[J]. PLoS Pathog,2013,9(8):e1003575.
[7]	Lamoth F, Calandra T. Early diagnosis of invasive mould infections and disease[J]. J Antimicrob Chemother,2017,72(1):19-28.
[8]	Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium[J]. Clin Infect Dis,2019,71(6):1367-1376.
[9]	Bassetti M, Azoulay E, Kullberg BJ, et al. EORTC/MSGERC definitions of invasive fungal diseases: summary of activities of the Intensive Care Unit Working Group[J]. Clin Infect Dis,2021,72(2):S121-S127.
[10]	《中华传染病杂志》编辑委员. 中国宏基因组学第二代测序技术检测感染病原体的临床应用专家共识[J]. 中华传染病杂志,2020,38(11):681-689.
[11]	张小艳，赵红，郑穗生, 等. 肺侵袭性曲霉菌感染的HRCT影像表现及其动态变化[J]. 中华全科医学,2019,17(3):443-447.
[12]	Sonnet S, Buitrago-Téllez CH, Tamm M, et al. Direct detection of angioinvasive pulmonaru Aspergillosis in immunosuppressed patients preliminary results with high-resolution 16-MDCT angiography[J]. Am J Roentgenol,2005,184(3):746751.
[13]	Rieger C, Herzog P, Eibel R, et al. Pulmonary MRI--a new approach for the evaluation of febrile neutropenic patients with malignancies[J]. Support Care Cancer,2008,16(6):599-606.
[14]	Sharma P, Mukherjee A, Karunanithi S, et al. Potential role of 18F-FDG PET/CT in patients with fungal infections[J]. Am J Roentgenol,2014,203(1):180-189.
[15]	Ankrah AO, Span LFR, Klein HC, et al. Role of FDG PET/CT in monitoring treatment response in patients with invasive fungal infections[J]. Eur J Nucl Med Mol Imaging,2019,46(1):174-183.
[16]	Kim T, Jung J, Song JS, et al. Correlation of fungal cultures from non-sterile sites and Galactomannan assay with the diagnosis of aspergillosis and mucormycosis based on sterile culture results and histopathologic findings[J]. Infect Dis (Lond),2019,51(5):373-376.
[17]	Kidd SE, Chen SC, Meyer W, et al. A new age in molecular diagnostics for invasive fungal disease: are we ready?[J]. Front Microbiol,2019,10:2903.
[18]	Arvanitis M, Anagnostou T, Mylonakis E. Galactomannan and polymerase chain reaction-based screening for invasive Aspergillosis among high-risk hematology patients: adiagnostic Meta-analysis[J]. Clin Infect Dis,2015,61(8):1263-1272.
[19]	Liu WD, Lin SW, Shih MC, et al. False-positive Aspergillus galactomannan immunoassays associated with intravenous human immunoglobulin administration[J]. Clin Microbiol Infect,2020,26(11):1555.e9-1555.e14.
[20]	Ullmann AJ, Aguado JM, Arikan-Akdagliet S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline[J]. Clin Microbiol Infect,2018,24(1):e1-e38.
[21]	Aguado JM, Vázquez L, Fernández-Ruiz M, et al. Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial[J]. Clin Infect Dis,2015,60(3):405-414.
[22]	Chen Y, Feng W, Ye K, et al. Application of metagenomic next-generation sequencing in the diagnosis of pulmonary infectious pathogens from bronchoalveolar lavage samples[J]. Front Cell Infect Microbiol,2021,11:541092.
[23]	Crofts TS, Gasparrini AJ, Dantas J. Next-generation approaches to understand and combat the antibiotic resistome[J]. Nat Rev Microbiol,2017,15(7):422-434.
[24]	Hagiwara D, Takahashi H, Watanabe A, et al. Whole-genome comparison of Aspergillus fumigatus strains serially isolated from patients with aspergillosis[J]. J Clin Microbiol,2014,52(12): 4202-4209.
[25]	Gu W, Deng XD, Lee M, et al. Rapid pathogen detection by metagenomic next-generation sequencing of infected body fluids[J]. Nat Med,2021,27(1):115-124.
[26]	Opathy C, Gabaldon T. Recent trends in molecular diagnostics of yeast infections: from PCR to NGS[J]. FEMS Microbiol Rev,2019,43(5):517-547.
[27]	Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies[J]. Nat Rev Genet,2016,17(6):333-351.
[28]	Huang J, Jiang EL, Yang DL, et al. Metagenomic next-generation sequencing versus traditional pathogen detection in the diagnosis of peripheral pulmonary infectious lesions[J]. Infect Drug Resist,2020,13:567-576.
[29]	Zinter MS, Dvorak CC, Mayday MY, et al. Pulmonary metagenomic sequencing suggests missed infections in immunocompromised children[J]. Clin Infect Dis,2019,68(11):1847-1855.
[30]	Chen HB, Yin YY, Gao H, et al. Clinical utility of in-house metagenomic next-generation sequencing for the diagnosis of lower respiratory tract infections and analysis of the host immune response[J]. Clin Infect Dis,2020,71(4):S416-S426.
[31]	Filkins LM, Bryson AL, Miller ST, et al. Navigating clinical utilization of direct-from-specimen metagenomic pathogen detection: clinical applications, limitations, and testing recommendations[J]. Clin Chem,2020,66(11):1381-1395.

Please choose a citation manager

Content to export